Amylin Pharmaceuticals, a San Diego-based biotech company that operated from 1987 until its acquisition by Bristol-Myers Squibb in 2012, fundamentally reshaped how researchers and clinicians think about blood sugar control. The company brought two first-in-class diabetes drugs to market: pramlintide (sold as Symlin), a synthetic analog of the pancreatic hormone amylin, and exenatide (sold as Byetta), the first GLP-1 receptor agonist. Both drugs challenged the longstanding idea that insulin alone was sufficient for managing diabetes, and the science behind them continues to drive drug development today.
The Hormone That Inspired the Company
Amylin is a 37-amino-acid peptide hormone that pancreatic beta cells release alongside insulin whenever you eat. It responds to the same nutrients that trigger insulin, including glucose, fats, and amino acids, and the two hormones are stored together inside the same secretory granules and released in parallel.1PubMed. Co-secretion of amylin and insulin from cultured islet beta-cells: modulation by nutrient secretagogues, islet hormones and hypoglycemic agents But amylin does different things than insulin. Instead of shuttling glucose into cells, amylin slows gastric emptying, reduces food intake, and suppresses the release of glucagon, the hormone that tells the liver to dump glucose into the bloodstream.2PubMed Central. Role and Cytotoxicity of Amylin and Protection of Pancreatic Islet β-Cells from Amylin Cytotoxicity Together, insulin and amylin form a two-part system for keeping blood sugar stable after meals. The insight that half of that system was missing in people with diabetes became the founding premise of Amylin Pharmaceuticals.
Why Natural Amylin Cannot Be Used as a Drug
In people with type 2 diabetes, amylin does not simply vanish. It misfolds. The human version of the peptide has a tendency to clump together into sticky aggregates called amyloid deposits, which accumulate in the pancreatic islets. These aggregates are toxic to the very beta cells that produce amylin and insulin, creating a vicious cycle: as beta cells die, both hormones decline, and the disease progresses.3PubMed Central. Modulation of islet amyloid polypeptide induced β-cell toxicity and amyloid formation by serum albumin proteins Evidence now suggests that these deposits are not just a byproduct of type 2 diabetes but actively drive beta cell loss and dysfunction.4PubMed Central. Molecular Structure, Membrane Interactions, and Toxicity of the Islet Amyloid Polypeptide in Type 2 Diabetes Mellitus
This aggregation problem meant you could not simply inject natural human amylin as a therapy. It would clump up in a vial, in a syringe, or in the body. Amylin Pharmaceuticals needed to engineer a version that stayed soluble.
Designing Pramlintide
The solution came from studying rats. Rat amylin has several proline residues in positions where human amylin has amino acids that allow beta-sheet formation, which is the structural event that drives aggregation. Pramlintide is a synthetic analog of human amylin with three proline substitutions borrowed from the rat version. Molecular simulations have shown that all three substitutions are necessary to block the formation of the long beta-sheet structures that seed amyloid clumps, while still preserving the alpha-helical shape the peptide needs to bind its receptor and do its job.5Biophysical Journal. Conformation and Free Energy of Human Amylin and Pramlintide Monomers in Solution The result was a drug that mimicked natural amylin’s metabolic effects without the dangerous tendency to misfold.
Three Mechanisms in One Injection
Pramlintide works through three complementary mechanisms that each target a different piece of the post-meal blood sugar spike. Understanding all three helps explain why the drug was genuinely novel and not just another way to lower glucose.
The first mechanism is slowing gastric emptying. When food leaves the stomach more slowly, glucose trickles into the bloodstream rather than arriving in a rush. In healthy volunteers, a single 30-microgram dose of pramlintide roughly doubled the time it took for half a meal to leave the stomach compared to placebo.6PubMed. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition In people with type 1 and type 2 diabetes, the delay was even more pronounced, with half-emptying times stretching from about 90 minutes on placebo to over 260 minutes on pramlintide.7PubMed. Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus This slowed the peak rate at which meal-derived glucose appeared in the blood and also lowered the liver’s own glucose output.8PubMed Central. Effects of delayed gastric emptying on postprandial glucose kinetics, insulin sensitivity, and β-cell function
The second mechanism is glucagon suppression. In people with type 1 diabetes, the normal feedback that tells alpha cells to stop releasing glucagon after a meal is broken, and glucagon levels can actually rise when they should fall. Pramlintide corrected this. In clinical studies, the post-meal rise in glucagon was essentially abolished in pramlintide-treated patients, while placebo-treated patients showed the typical abnormal increase.9PubMed. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes Peak glucagon concentrations after breakfast dropped by roughly a third compared to placebo.10PubMed. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus A head-to-head comparison found that pramlintide suppressed meal-stimulated glucagon more effectively than the GLP-1 agonist liraglutide in type 1 diabetes, with the suppression persisting for at least four hours after eating.11The Journal of Clinical Endocrinology & Metabolism. Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes
The third mechanism is reduced appetite. Amylin acts on a brain region called the area postrema, which sits outside the blood-brain barrier and monitors circulating signals related to energy balance. Amylin receptors in this region trigger pathways that promote a feeling of fullness and reduce meal size.12PubMed. Brainstem mechanisms of amylin-induced anorexia This satiety effect is what links pramlintide’s blood sugar benefits to its weight effects.
What Pramlintide Did in Clinical Trials
The combination of these mechanisms translated into meaningful improvements in blood sugar control. In people with type 1 diabetes, pramlintide lowered mean 24-hour glucose readings by about 1.2 mmol/L compared to placebo, primarily by flattening the post-meal spikes that are hardest to manage with insulin alone.13Diabetes Care. Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study Glucose variability also improved, which matters because the swings between highs and lows are themselves associated with complications and carry a direct quality-of-life cost. In one analysis, pramlintide brought post-meal blood glucose down from about 175 mg/dL on placebo to roughly 151 mg/dL, without increasing the risk of pre-meal hypoglycemia.14PubMed Central. Pramlintide Reduces the Risks Associated with Glucose Variability in Type 1 Diabetes
In type 2 diabetes, a year-long trial showed that pramlintide (120 micrograms twice daily) as an add-on to insulin improved HbA1c while the placebo group saw no change. That glycemic benefit was accompanied by modest weight loss of about 1.4 kilograms at one year, compared to a 0.7-kilogram gain in the placebo group.15Diabetes Care. Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes: A 1-year randomized controlled trial In type 1 diabetes trials over the same duration, weight drifted down in the pramlintide groups while it crept up on placebo, even without any specific dietary intervention.16PubMed. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial
Weight Loss as a Standalone Indication
The appetite-reducing properties of pramlintide prompted Amylin Pharmaceuticals to test the drug specifically for obesity, outside of diabetes. A 12-month trial in obese adults without diabetes showed that pramlintide combined with a lifestyle program produced substantially more weight loss than lifestyle intervention plus placebo. At one year, the highest-dose pramlintide groups lost about 6 to 7 kilograms more than placebo, and roughly 40 percent of participants in those groups lost 10 percent or more of their body weight, compared to 12 percent on placebo.17PubMed Central. Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity These results were considered promising at the time, though the drug was never approved for obesity as a standalone indication. The weight trajectory was telling, however: placebo-treated participants regained the weight they had initially lost by four months, while pramlintide groups maintained and even extended their losses through the full year.
The Safety Trade-Off That Limited Adoption
Pramlintide reached the market with two well-known side effects that constrained how widely it was prescribed. The first was nausea, which was the most common reason patients stopped taking the drug. The second was hypoglycemia. Because pramlintide slows glucose absorption from food while the patient’s pre-meal insulin dose is calibrated for unslowed absorption, blood sugar can drop too low, especially in the early weeks of treatment. In the first four weeks, the rate of severe hypoglycemia was two to four times higher in pramlintide groups than in placebo groups.18PubMed Central. Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes The manufacturer addressed this with a blanket recommendation: cut your pre-meal insulin dose by 50 percent when starting pramlintide, then titrate back up.19Clinical Therapeutics. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus
Beyond the biological risks, there was a practical barrier. Pramlintide and insulin cannot be mixed in the same syringe because of stability issues, which means patients who use pramlintide need a separate injection before each meal on top of their existing insulin injections.20The Journal of Pharmacology and Experimental Therapeutics. Pramlintide an Adjunct to Insulin Therapy: Challenges and Recent Progress in Delivery For someone already taking four or more injections a day, adding three more was a hard sell. Delivering both hormones through a single device has been a longstanding engineering challenge, complicated by the different physical and chemical properties of the two peptides.21PubMed Central. Engineering biopharmaceutical formulations to improve diabetes management Pramlintide remained on the market but was never widely adopted, settling into a niche role for motivated patients who wanted flatter post-meal glucose profiles and were willing to manage the extra complexity.
Exenatide and the Birth of the GLP-1 Drug Class
Amylin Pharmaceuticals’ other major contribution to diabetes treatment was arguably even more consequential than pramlintide. Exenatide, derived from a peptide found in the saliva of the Gila monster lizard, became the first GLP-1 receptor agonist approved for type 2 diabetes. In preclinical models, exenatide enhanced glucose-dependent insulin secretion, suppressed inappropriately high glucagon, slowed gastric emptying, reduced body weight, and appeared to preserve beta cell function.22PubMed Central. Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1 Clinical trials confirmed that both the twice-daily and once-weekly formulations reduced blood sugar and were associated with weight loss in people with type 2 diabetes.
The once-weekly version, marketed as Bydureon, was a drug delivery innovation in its own right. The active peptide was encapsulated in tiny biodegradable microspheres that slowly released exenatide over weeks as the polymer matrix broke down in the body. Plasma levels reached the therapeutic range within about two weeks and hit steady state by six to seven weeks. This gradual ramp-up also seemed to reduce the nausea that bothered patients on the twice-daily version.23PubMed Central. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes In comparative trials, the once-weekly formulation lowered HbA1c more than the twice-daily version, as well as more than sitagliptin, pioglitazone, or insulin glargine.
Exenatide opened the door for the entire GLP-1 receptor agonist class, which now includes blockbuster drugs like liraglutide, dulaglutide, and semaglutide. The commercial and clinical success of these later agents has somewhat overshadowed exenatide itself, but the path they walk was cut by Amylin Pharmaceuticals’ development program.
Cagrilintide, CagriSema, and the Amylin Revival
For years after Amylin Pharmaceuticals was absorbed into Bristol-Myers Squibb, amylin-based therapy seemed to have stalled. Pramlintide was still available but rarely prescribed, and the excitement in the field had shifted entirely to GLP-1 drugs. That changed when Novo Nordisk developed cagrilintide, a next-generation amylin analog designed for once-weekly dosing. Unlike pramlintide, which requires injections before every meal, cagrilintide is a long-acting, lipidated molecule engineered for slow absorption and extended activity.24PubMed. Development of Cagrilintide, a Long-Acting Amylin Analogue In clinical trials, cagrilintide has produced significant weight loss both alone and in combination with semaglutide.
The most ambitious application of this revival is CagriSema, a co-formulation that combines cagrilintide with semaglutide in a single weekly injection. The idea is that amylin and GLP-1 agonists work through partially overlapping but distinct pathways, and combining them produces greater effects on appetite, glucose control, and weight than either drug alone.25PubMed Central. Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity Animal studies have shown that amylin analogs and GLP-1 analogs together produce what researchers describe as synergistic-like reductions in energy intake and body weight, meaning the combined effect exceeds what you would expect from simply adding the individual effects together.26PubMed Central. Combined GLP-1 Receptor Agonist and Amylin Analogue Pharmacotherapy to Treat Obesity Comorbid With Type 1 Diabetes In clinical trials, CagriSema has achieved greater effects than either component alone on both glucose regulation and weight management.27PubMed. Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes
This development represents a direct continuation of the science Amylin Pharmaceuticals originally commercialized. The core concept, that replacing amylin alongside other hormones produces better metabolic outcomes than managing insulin alone, has been validated decades after the company first championed it. The practical barriers that held pramlintide back, particularly the need for multiple daily injections and its short duration of action, are exactly what cagrilintide’s engineering was designed to solve.
A Surprising Second Life in Alzheimer’s Research
One of the more unexpected legacies of amylin research is its intersection with Alzheimer’s disease. This might seem counterintuitive, given that amylin’s tendency to form toxic aggregates in the pancreas mirrors the amyloid-beta plaques that characterize Alzheimer’s. But in mouse models of the disease, both natural amylin and pramlintide have shown neuroprotective effects. In one study, amylin treatment reduced amyloid plaque size and intensity in the cortex, hippocampus, and thalamus of Alzheimer’s model mice, lowered levels of the toxic amyloid-beta 1-42 peptide in brain tissue, and appeared to promote clearance of amyloid into cerebrospinal fluid. Pramlintide produced similar benefits in a second mouse model.28Molecular Psychiatry. Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer’s disease
Separate work has shown that pramlintide improved cognitive function in Alzheimer’s disease models and affected the enzymes responsible for processing amyloid, while also regulating the brain’s own antioxidant defenses.29PubMed Central. Neuroprotective Effects of the Amylin Analog, Pramlintide, on Alzheimer’s Disease Are Associated with Oxidative Stress Regulation Mechanisms These findings remain preclinical, and there is a long distance between improving cognition in mice and treating human Alzheimer’s disease. But the research has expanded the scientific understanding of amylin receptors from a purely metabolic context into neuroscience, and it has generated interest in whether the amylin receptor system might be a druggable target for neurodegeneration.
The Complexity of Amylin Receptor Pharmacology
Part of the reason amylin’s biology took so long to translate into widely used drugs is the sheer complexity of its receptor system. Unlike most hormones, which bind to a single dedicated receptor, amylin acts through several receptor subtypes that are assembled from a core protein shared with other signaling systems. These receptors also respond to other peptides such as calcitonin gene-related peptide, which creates crosstalk between metabolic and vascular signaling pathways.30Comprehensive Physiology. Systemic and Central Amylin, Amylin Receptor Signaling, and Their Physiological and Pathophysiological Roles in Metabolism This pharmacological messiness made it difficult to design drugs that cleanly activated the right receptors without unwanted effects, and it continues to inform how second-generation analogs like cagrilintide are optimized. Recent structural work on these receptor complexes has accelerated the process, allowing chemists to design molecules with more selective binding profiles than pramlintide offered.
The receptor complexity also helps explain why amylin’s effects extend beyond simple blood sugar control into appetite regulation, gastric motility, and possibly neuroprotection. Each of these actions involves different tissues expressing different subtypes of the receptor, and a drug’s profile depends on how it interacts with the full family rather than just one member. This is an area of active research, and it is likely that the next generation of amylin-based drugs will be designed with specific receptor subtype selectivity in mind, which could separate desired effects from side effects more cleanly than pramlintide was able to do.